Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMGN - ImmunoGen, Inc.

Close
31.23
0   0%

Share volume: 0
Last Updated: Fri 09 Feb 2024 10:00:01 PM CET
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
$31.23
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 33%
Dept financing 39%
Liquidity 52%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$31.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$0.28
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
266.264 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Mark J. Enyedy
Region: US
Website: immunogen.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

ImmunoGen, Inc. develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.

Recent news